TScan Therapeutics: chief legal and strategy officer Zoran Zdraveski received 300,000 shares

What happened

• The filing reports that Zoran Zdraveski, chief legal and strategy officer, received 300,000 restricted stock units (RSUs) on Oct 1, 2026 at $0.00, total $0.00.

Key details

• Transaction date and price: Oct 1, 2026 at $0.00 per share.
• Shares owned after the transaction: not reported in the filing.
• Footnote: 25% of the RSUs vest on Sep 30, 2028; the remaining 75% vest on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) Sep 30, 2030, subject to continued service and the terms of the issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement.
• Filing date: Oct 2, 2026; no late filing flag is indicated in the report.

Why it may matter

• Award: these 300,000 RSUs were an equity award, not a market sale or purchase, and are subject to the vesting conditions described above.
• 10% owner/executive status: the filing lists the insider as chief legal and strategy officer.
• A filing does not show why the insider traded or why the company acted.